Liddle Syndrome
Presentation :
- Clinically resembles primary aldosteronism, with hypertension, hypokalemia and metabolic alkalosis, BUT with low plasma renin and aldosterone levels
- Diagnosis is suggested by the presence of hypertension in a young patient, particularly one with a positive family history.
Pathophysiology :
- Caused by mutations to subunits of the Epithelial Sodium Channel (ENaC)
- Mutations typically prevent ubiquitination of these subunits, slowing the rate at which they are internalized from the membrane, resulting in an elevation of channel activity
- Mutations can also increase ENaC activity by increasing the probability that ENaC channels within the membrane are open
Diagnostic Testing:
- Low urine sodium (< 20 mmol/L), low plasma renin and aldosterone levels, and response to empiric treatment usually are considered sufficient to confirm the diagnosis.
- Definitive diagnosis can be achieved through genetic testing
Treatment :
- Triamterene 100-200mg PO BID and Amiloride 5-20mg PO QD are effective as they block ENaC channels.
- Note: spironolactone is ineffective as it lacks this ENaC activity
Prognosis:
References:
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731958/
- https://www.merckmanuals.com/professional/genitourinary-disorders/renal-transport-abnormalities/liddle-syndrome
Created at: periodic/daily/August/2023-08-05-Saturday